CGP 40774

Drug Profile

CGP 40774

Alternative Names: JT 3003

Latest Information Update: 20 Mar 2002

Price : $50

At a glance

  • Originator Novartis
  • Developer Jenner Biotherapies (CEASED)
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Mucositis; Myelosuppression

Most Recent Events

  • 20 Mar 2002 No development reported for cancer, myelosuppression or mucositis in the USA
  • 30 Jul 1998 No-Development-Reported for Mucositis in USA (PO)
  • 30 Jul 1998 No-Development-Reported for Myelosuppression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top